万赛维的用法和用量

It is a special antiviral drug mainly used for primary immunodeficiency diseases, cytomegalovirus (CMV) infection, cytomegalic inclusion disease, idiopathic thrombocytopenic purpura, and immune thrombocytopenic purpura. It is suitable for the prevention of cytomegalovirus infection in high-risk solid organ transplant patients and the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS), that is, AIDS patients.

What is the usage and dosage of Vansavi?

Standard dosage: Vancevi tablets are administered orally and should be taken with food. Vansevir tablets can be rapidly converted into ganciclovir in large quantities. The bioavailability of valganciclovir hydrochloride tablets as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, so the dosage and usage instructions of valganciclovir hydrochloride tablets described below should be strictly followed.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. Prophylaxis of CMV Infection in Transplant Patients: For patients who have received a solid organ transplant, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Special Dosage Guidelines in Patients with Renal Impairment: Serum creatinine or creatinine clearance levels should be monitored closely. Dosage adjustments should be made based on creatinine clearance as shown below. For CrCl ≥ (greater than or equal to) 60 mL/min, the induction dose is 900 mg, twice a day; the maintenance dose is 900 mg, once a day. If the CrCl is 40-59 mL/min, the induction dose is 450 mg, twice a day; the maintenance dose is 450 mg, once a day. If the CrCl is 25-39 mL/min, the induction dose is 900 mg, once a day; the maintenance dose is 900 mg, once every other day. If the CrCl is 10-24 mL/min, the induction dose is 900 mg, once every other day; the maintenance dose is 900 mg, twice a week. The creatinine clearance rate can be estimated based on serum creatinine according to the following formula: Male = [140-age (years) x weight (kg) ÷ (72) x [0.011 x serum creatinine (umol/L)]. Female = 0.85 × male value. Patients undergoing hemodialysis: For patients undergoing hemodialysis (CrCl<10 mL/min), no recommended dose can be given, so Vancevi cannot be used in such patients. Patients with severe leukopenia, neutropenia, anemia, thrombocytopenia and pancytopenia: Cases of severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow suppression and aplastic anemia have occurred in patients treated with Vancevir (or cyclovir). Treatment cannot be started if the absolute neutrophil count is less than 500/uL, the platelet count is less than 25,000/uL, or the hemoglobin is less than 8 g/dl.